Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

Kaiser Permanente

Status

Enrolling

Conditions

Influenza

Community-acquired Pneumonia

Cardiovascular Events

Treatments

Biological: High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)

Biological: Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4)

Study type

Observational

Funder types

Other

Industry

Identifiers

NCT06029933

2033496

Details and patient eligibility

About

This study will evaluate the relative vaccine effectiveness of quadrivalent adjuvanted inactivated influenza vaccine (aIIV4) versus quadrivalent high-dose inactivated influenza vaccine (HD-IIV4) in preventing polymerase chain reaction (PCR)-confirmed influenza and influenza-related outcomes in adults ≥65 years of age during the 2023/24 and 2024/25 influenza seasons. The study is an observational study conducted at Kaiser Permanente Northern California (KPNC), an integrated health care system in the United States.

Enrollment

960,000 estimated patients

Sex

All

Ages

65+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Age ≥65 years at the time of influenza vaccination
KPNC member at the time of vaccination
Receive either aIIV4 or HD-IIV4 at a KPNC facility during the 2023/24 and/or 2024/25 influenza seasons

Exclusion criteria

Age <65 years at the time of influenza vaccination
Received either aIIV4 or HD-IIV4 in the inpatient setting
Receive more than one influenza vaccination during a single season period (i.e., 2023/24 or 2024/25 influenza seasons)
Receive an influenza vaccination outside of KPNC